Yesterday, Morgan Stanley released a report by their head of biotech research, Matthew Harrison, which has the following prognosis:
Morgan Stanley: “While we understand the desire for optimism, we also caution that the US outbreak is far from over. Recovering from this acute period in the outbreak is just the